Healthcare Private Placement and M&A Transactions Review Week Ending June 2, 2024

Koios Medical: The company raised $130 million of venture funding in the form of convertible debt from undisclosed investors on May 28, 2024. The company is a developer of an ultrasound image analysis platform intended to offer early disease detection and diagnosis.

Gameto: The company raised $33 million of  Series B venture funding in a deal led by Two Sigma Ventures and RA Capital Management on May 29, 2024, putting the company’s pre-money valuation at $87 million. Insight Partners, Ingeborg Investments, Future Ventures, Bold Capital Partners, Chelsea Hirschhorn and Stacey Bendet Eisner also participated in the round. The company is an operator of a biotechnology company intended to solve diseases of the female reproductive system.

Lucy Therapeutics: The company raised $12.5 million of Series A venture funding led by Engine Ventures and Safar Partners on May 28, 2024. Parkinson’s UK, Bill Gates, Michael J. Fox Foundation, and other undisclosed investors also participated in the round. The company is a developer of proprietary mitochondrial-based small molecule therapies and diagnostic biomarkers designed for the central nervous system.

Aviceda Therapeutics: The company raised $19 million of venture funding from undisclosed investors on May 31, 2024. The company is an operator of a biotechnology business intended to develop breakthrough glycol-therapeutics for patients.

Volastra: The company raised $15 million of venture funding from undisclosed investors on May 30, 2024. The company is an operator of a drug discovery and therapeutics company intended to treat and prevent the formation of metastatic disease.

Kythera: The company raised $9.2 million of venture funding through a combination of debt and equity from undisclosed investors on May 29, 2024. The company is a developer of a data management and analytics platform designed to process healthcare data.

Munice: The company is in process of raising $2 million of an undisclosed targeted amount of venture funding on May 31, 2024. The company is a developer of a sleep induction application designed to treat sleeping disorders.

Carrick Therapeutics: The company raised an undisclosed amount of venture funding from B Capital Group in June 2024. The company is a developer of oncology therapeutics.

ShockWave Medical / Johnson & Johnson: The company was acquired by Johnson & Johnson for $13.1 billion on May 31, 2024. Shockwave Medical Inc is a medical device company focused on developing and commercializing novel technologies that transform the care of patients with cardiovascular disease.

Inhibrx / Sanofi: The company was acquired by Sanofi for an estimated $1.9 billion on May 30, 2024. Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates for people with life-threatening conditions.

EyeBio / Merck & Co.: The company reached a definitive agreement to be acquired by Merck & Co. for $1.3 billion as of May 29, 2024. EyeBio is an operator of an ophthalmology biotechnology company designed to develop vision therapy to protect, restore, and improve vision.

Surmodics / GTCR: The company entered into a definitive agreement to be acquired by GTCR through an estimated $627 million public-to-private LBO on May 29, 2024. Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry.

Akili Interactive / Virtual Therapeutics: The company reached a definitive agreement to be acquired by Virtual Therapeutics for $34 million on May 29, 2024. Akili Inc is a digital medicine company pioneering the development of digital cognitive treatments.